This funding surge comes as the company continues to advance the application of generative AI through its platform, Geneva OS.
The investment round was spearheaded by Valtruis, with substantial contributions from Cencora Ventures, McKesson Ventures, and Merck Global Health Innovation Fund, in addition to the continued support of existing backers like Breyer Capital, Emerson Collective, and Presidio Ventures.
Addressing real-world evidence challenges
“Atropos Health addresses a very real problem that both health systems and pharmaceutical manufacturers face in turning medical data into insights in a timely, predictable, and cost-effective manner,” said Michelle Snyder, partner at McKesson Ventures.
Founded in 2019 by Brigham Hyde, Nigam Shah, and Saurabh Gombar, Atropos Health originated as the ‘Green Button’ project at Stanford University. The founders are prominent figures in the intersection of AI and real-world evidence (RWE) research, aiming to democratize access to high-quality RWE to enhance healthcare decision-making and outcomes.
Generative AI and ChatRWD transforming evidence production
Atropos Health’s product, ChatRWD, uses generative AI to drastically reduce the time needed to produce high-quality, publication-grade real-world evidence from months to mere minutes. This tool is built on the GENEVA OS framework, which ensures the integrity and security of large language models (LLMs) while mitigating the risk of hallucinations, a critical feature for clinical evidence reliability.
“As excitement over the application of Generative AI technology in healthcare turns from potential to practical applications, the focus of providers, life sciences, and other healthcare stakeholders turns to quality, transparency, and automation backed by tangible ROI,” said Brigham Hyde, CEO and co-founder of Atropos Health.”
Driving value-based care
The new funds will bolster Atropos Health’s initiatives in value-based care. Their suite of evidence-generating applications aids in providing comprehensive care and supports value-based performance metrics. Partners, including Arcadia, benefit from accelerated clinical decision-making processes that are both high-value and low-cost.
Mike Spadafore, managing director of Valtruis, said: “For nearly 15 years, I’ve had a front-row seat to value-based care’s evolution and positive impact on patients, physicians, and communities. I am excited about Atropos Health and its ability to automate personalized, real-world evidence at scale for both providers and researchers.”
Strategic partnerships and expansion
With its new funding, Atropos Health plans to deepen its relationships within the life sciences sector and vertically integrated healthcare providers. A notable collaboration is with Cencora, a prominent global pharmaceutical solutions organization. This partnership aims to apply Atropos Health’s real-world evidence platform to oncology and specialty care, crucial areas in the evolving landscape of cancer treatment.
“Atropos Health addresses a very real problem that both health systems and pharmaceutical manufacturers face in turning medical data into insights in a timely, predictable, and cost-effective manner,” said Snyder. “As leading industry players increasingly recognize the value of having the right data, rather than just having the most data, Atropos Health stands out in its ability to understand and score datasets in a compliant and secure manner in order to accelerate research and improve patient outcomes.”
Future prospects
With the Series B funding, Atropos Health is poised to revolutionize the healthcare industry further by enhancing the capabilities of ChatRWD and expanding the Atropos Evidence Network. This expansion includes critical vertical integrations in oncology and other specialty areas, leveraging millions of anonymized patient data to create high-quality evidence that supports both clinical and research needs.
The company says its commitment to transparency, accuracy, and speed in evidence generation promises to set new standards in the healthcare industry, making high-quality, personalized real-world evidence accessible and practical for all stakeholders involved.
